Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Investment analysts at Jefferies Group upped their FY2017 earnings per share (EPS) estimates for shares of Vanda Pharmaceuticals in a note issued to investors on Wednesday. Jefferies Group analyst M. Andrews now expects that the biopharmaceutical company will earn ($0.43) per share for the year, up from their prior estimate of ($0.53). Jefferies Group currently has a “Buy” rating and a $21.00 target price on the stock. Jefferies Group also issued estimates for Vanda Pharmaceuticals’ Q4 2017 earnings at ($0.13) EPS.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.10). The firm had revenue of $41.30 million for the quarter, compared to analysts’ expectations of $43.90 million. Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The firm’s revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the company earned ($0.01) earnings per share.
Several other equities analysts have also commented on the stock. Zacks Investment Research lowered shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, October 26th. Piper Jaffray Companies increased their price target on shares of Vanda Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Thursday, September 14th. Oppenheimer Holdings, Inc. set a $26.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, October 29th. Finally, BidaskClub upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 22nd. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $21.50.
Shares of Vanda Pharmaceuticals (VNDA) opened at $12.95 on Monday. Vanda Pharmaceuticals has a 1-year low of $11.90 and a 1-year high of $18.99.
A number of institutional investors have recently made changes to their positions in VNDA. Legal & General Group Plc increased its stake in Vanda Pharmaceuticals by 37.4% in the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after purchasing an additional 3,022 shares during the last quarter. Kopp Investment Advisors LLC purchased a new position in shares of Vanda Pharmaceuticals during the second quarter worth approximately $196,000. Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Vanda Pharmaceuticals during the third quarter worth approximately $277,000. American International Group Inc. grew its position in shares of Vanda Pharmaceuticals by 7.1% during the first quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock worth $316,000 after acquiring an additional 1,491 shares during the last quarter. Finally, Voya Investment Management LLC grew its position in shares of Vanda Pharmaceuticals by 29.7% during the second quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock worth $328,000 after acquiring an additional 4,605 shares during the last quarter. Institutional investors own 87.28% of the company’s stock.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.